CERO THERAPEUTICS HOLDINGS, INC.

Phoenix Biotech Acquisition Corp, trading under ticker PBAX, was a blank-check company sponsored by Phoenix Biotech Sponsor, LLC that priced its IPO in 2021 with a stated focus on the biotechnology and life sciences sector. The SPAC completed its business combination with Cero Therapeutics, a clinical-stage biotherapeutics company developing chimeric engulfment receptor T cell therapies targeting cancer, with the combined entity continuing to operate as Cero Therapeutics Holdings, Inc. The company filed its annual 10-K report on April 2, 2024, reflecting its status as a post-merger publicly traded oncology-stage enterprise. Sign up for SpacDesk to access the full filing history, deal timeline, and institutional data for PBAX and thousands of other SPAC transactions.